China Jo-Jo Drugstores, Inc. (CJJD) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören China Jo-Jo Drugstores, Inc. (CJJD), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 42/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026China Jo-Jo Drugstores, Inc. (CJJD) Sağlık ve Boru Hattı Genel Bakışı
China Jo-Jo Drugstores, Inc. retails and distributes pharmaceutical and healthcare products in China, operating through retail drugstores, online platforms, wholesale, and herb farming. With a focus on traditional Chinese medicine (TCM) and Western medicine, the company operates retail pharmacies and online stores, facing competition in China's evolving healthcare market.
Yatırım Tezi
China Jo-Jo Drugstores, Inc. presents a unique investment proposition within the Chinese healthcare market, characterized by its integrated approach to retail pharmacy, online sales, wholesale distribution, and herb farming. With a market capitalization of $0.01 billion and a P/E ratio of 1.20, the company's valuation metrics suggest potential undervaluation relative to its earnings. The company's profit margin of 8.5% and gross margin of 3.2% indicate areas for improvement in operational efficiency and cost management. Key growth catalysts include expanding its online pharmacy presence to capitalize on the growing e-commerce trend in China, and leveraging its TCM herb farming operations to meet increasing demand for traditional medicine. However, investors may want to evaluate the potential risks associated with operating in a highly regulated market, including evolving healthcare policies and pricing pressures. The company's beta of -0.15 suggests a low correlation with the broader market, potentially offering downside protection during market downturns.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.01 billion, indicating a small-cap company with potential for growth.
- P/E ratio of 1.20, suggesting the company may be undervalued compared to its earnings.
- Profit margin of 8.5%, reflecting the company's profitability in the pharmaceutical retail sector.
- Gross margin of 3.2%, indicating the percentage of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services it sells.
- Operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores as of March 31, 2021, demonstrating a significant retail presence.
Rakipler & Benzerleri
Güçlü Yönler
- Established retail pharmacy network in China.
- Integration of traditional Chinese medicine (TCM) with Western medicine.
- Online pharmacy platform providing convenient access to healthcare products.
- Herb farming operations ensuring a stable supply of TCM ingredients.
Zayıflıklar
- Relatively small market capitalization compared to larger competitors.
- Gross margin of 3.2% indicates potential inefficiencies.
- Limited geographic diversification outside of China.
- Dependence on regulatory approvals for pharmaceutical products.
Katalizörler
- Upcoming: Expansion of online pharmacy platform to increase market reach and sales.
- Ongoing: Leveraging TCM expertise to develop new products and services for domestic and international markets.
- Upcoming: Strategic partnerships with other healthcare providers or technology companies to enhance capabilities.
- Ongoing: Efforts to improve operational efficiency and increase profit margins.
Riskler
- Potential: Intense competition from other pharmaceutical retailers and online pharmacies.
- Ongoing: Evolving healthcare regulations and pricing pressures in China.
- Potential: Product recalls or safety concerns related to pharmaceutical products.
- Potential: Fluctuations in the cost of raw materials for TCM herbs.
- Ongoing: Dependence on regulatory approvals for pharmaceutical products.
Büyüme Fırsatları
- Expansion of Online Pharmacy Platform: China Jo-Jo Drugstores can capitalize on the increasing e-commerce penetration in China by expanding its online pharmacy platform. The Chinese online pharmacy market is projected to reach $49.7 billion in 2026, presenting a significant growth opportunity. By enhancing its online platform with a wider range of products, improved user experience, and strategic partnerships with e-commerce giants, the company can attract a larger customer base and drive online sales growth. Timeline: Ongoing.
- Leveraging Traditional Chinese Medicine (TCM): With the growing popularity of TCM in China and globally, China Jo-Jo Drugstores can leverage its herb farming operations to meet the increasing demand for TCM products. The global TCM market is expected to reach $200 billion by 2025. By expanding its herb cultivation and processing capabilities, the company can ensure a stable supply of high-quality TCM ingredients and develop new TCM-based products for both domestic and international markets. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: China Jo-Jo Drugstores can pursue strategic partnerships and acquisitions to expand its market reach and product offerings. Collaborating with other healthcare providers, pharmaceutical manufacturers, or technology companies can create synergies and enhance the company's competitive position. Acquiring smaller pharmacy chains or healthcare-related businesses can accelerate its expansion into new geographic areas or product categories. Timeline: Upcoming.
- Enhancing Retail Pharmacy Network: While already having a retail presence, China Jo-Jo Drugstores can optimize its existing network of retail pharmacies by improving store layouts, product assortment, and customer service. Implementing data analytics to understand customer preferences and optimize inventory management can enhance sales and profitability. Expanding the range of healthcare services offered at its pharmacies, such as health screenings and consultations, can also attract more customers. Timeline: Ongoing.
- Expanding Drug Wholesale Business: China Jo-Jo Drugstores can increase its revenue by expanding its drug wholesale business. By establishing partnerships with more pharmaceutical manufacturers and distributors, the company can increase the volume of products it distributes. Focusing on niche or specialized pharmaceutical products can also provide a competitive advantage. Timeline: Ongoing.
Fırsatlar
- Expansion of online pharmacy platform to reach more customers.
- Leveraging TCM expertise to develop new products and services.
- Strategic partnerships and acquisitions to expand market reach.
- Increasing demand for healthcare products and services in China.
Tehditler
- Intense competition from other pharmaceutical retailers and online pharmacies.
- Evolving healthcare regulations and pricing pressures in China.
- Potential for product recalls or safety concerns.
- Fluctuations in the cost of raw materials for TCM herbs.
Rekabet Avantajları
- Established retail pharmacy network in China.
- Integration of traditional Chinese medicine (TCM) with Western medicine.
- Online pharmacy platform providing convenient access to healthcare products.
- Herb farming operations ensuring a stable supply of TCM ingredients.
CJJD Hakkında
Founded in 2003 and headquartered in Hangzhou, China, China Jo-Jo Drugstores, Inc. has evolved into a multifaceted healthcare company operating across various segments of the pharmaceutical industry. The company's primary business involves retailing and distributing pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices. These products are offered through its network of retail drugstores, operating under the Jiuzhou Grand Pharmacy name, and its online pharmacy platforms. The company also provides convenience products, such as consumable, seasonal, and promotional items. China Jo-Jo Drugstores distinguishes itself by integrating traditional and Western medical practices, offering on-site consultations with licensed doctors of Western medicine and TCM. This approach caters to a broad customer base seeking both conventional and alternative healthcare solutions. In addition to its retail operations, the company engages in drug wholesale, distributing third-party pharmaceutical products to trading companies. It also cultivates and wholesales herbs used for TCM, further diversifying its revenue streams. As of March 31, 2021, China Jo-Jo Drugstores operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, along with 4 additional drugstores, demonstrating its established presence in the Chinese pharmaceutical retail market.
Ne Yaparlar
- Operates retail drugstores under the Jiuzhou Grand Pharmacy name.
- Sells prescription and over-the-counter drugs.
- Offers nutritional supplements and traditional Chinese medicines (TCM).
- Provides personal and family care products and medical devices.
- Operates an online drugstore retailing OTC drugs and nutritional supplements.
- Sells products through third-party online platforms.
- Distributes third-party pharmaceutical products to trading companies.
- Cultivates and wholesales herbs used for TCM.
İş Modeli
- Retail sales of pharmaceutical products through physical stores.
- Online sales of pharmaceutical products through its online pharmacy.
- Wholesale distribution of pharmaceutical products to other companies.
- Cultivation and sale of herbs used in traditional Chinese medicine.
Sektör Bağlamı
China Jo-Jo Drugstores operates within the rapidly evolving Chinese healthcare market, which is characterized by increasing demand for pharmaceutical products and healthcare services. The market is driven by factors such as an aging population, rising disposable incomes, and growing awareness of health and wellness. The competitive landscape includes both domestic and international players, ranging from large pharmaceutical manufacturers to retail pharmacy chains. China Jo-Jo Drugstores differentiates itself through its integrated business model, combining retail pharmacy, online sales, wholesale distribution, and herb farming. The company's focus on traditional Chinese medicine (TCM) also provides a unique selling proposition in a market where TCM remains highly valued.
Kilit Müşteriler
- Individual consumers seeking prescription and over-the-counter medications.
- Customers interested in nutritional supplements and personal care products.
- Patients seeking traditional Chinese medicine (TCM) remedies.
- Trading companies purchasing pharmaceutical products for distribution.
Finansallar
Grafik & Bilgi
China Jo-Jo Drugstores, Inc. (CJJD) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
benzinga · 22 Ağu 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · 14 Ağu 2023
-
Stocks That Hit 52-Week Lows On Friday
· 20 Ağu 2021
-
Stocks Which Set New 52-Week High Yesterday, October 31st
· 1 Kas 2018
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
CJJD için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
CJJD için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, CJJD'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Friday
Stocks Which Set New 52-Week High Yesterday, October 31st
Yönetim: Lei Liu
CEO
Lei Liu is the Chief Executive Officer of China Jo-Jo Drugstores, Inc. His background encompasses extensive experience in the pharmaceutical retail sector in China. Details regarding his specific educational background and prior roles are not available. As CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. He manages a workforce of 939 employees.
Sicil: Since becoming CEO, Lei Liu has focused on expanding the company's online presence and leveraging its traditional Chinese medicine (TCM) capabilities. Specific milestones and achievements under his leadership are not available, but the company continues to operate in a competitive market. He is responsible for navigating the evolving regulatory landscape and driving growth in the Chinese healthcare market.
Yatırımcılar China Jo-Jo Drugstores, Inc. (CJJD) Hakkında Ne Soruyor
CJJD için değerlendirilmesi gereken temel faktörler nelerdir?
China Jo-Jo Drugstores, Inc. (CJJD) şu anda yapay zeka skoru 42/100, düşük puanı gösteriyor. Temel güçlü yan: Established retail pharmacy network in China.. İzlenmesi gereken birincil risk: Potential: Intense competition from other pharmaceutical retailers and online pharmacies.. Bu bir finansal tavsiye değildir.
CJJD MoonshotScore'u nedir?
CJJD şu anda MoonshotScore'da 42/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
CJJD verileri ne sıklıkla güncellenir?
CJJD fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler CJJD hakkında ne diyor?
CJJD için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
CJJD'a yatırım yapmanın riskleri nelerdir?
CJJD için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from other pharmaceutical retailers and online pharmacies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
CJJD'ın P/E oranı nedir?
CJJD için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için CJJD'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
CJJD aşırı değerli mi, yoksa düşük değerli mi?
China Jo-Jo Drugstores, Inc. (CJJD)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
CJJD'ın temettü verimi nedir?
China Jo-Jo Drugstores, Inc. (CJJD) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data and may be subject to change.
- AI analysis is pending for CJJD, which may provide further insights.
- The Chinese healthcare market is subject to regulatory and economic uncertainties.